The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the safety and efficacy of deferoxamine (DFO) combined with conventional transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jinan Military General Hospital
• Treatments: Chlorotrianisene; Deferoxamine

Criteria

Inclusion Criteria:

• Adult patients, ≥ 18 years of age.

• The participant must have histologically-confirmed, unresectable HCC

• At least 1 measurable lesion, and overall tumor lesions occupying < 50% of liver volume

• The participant has provided signed informed consent

• No known allergy to contrast media

• Not pregnant

• No vascular anatomy or bleeding that would preclude catheter placement or emboli injection

Exclusion Criteria:

• Patients receiving concurrent radiotherapy or immunotherapy.

• Patients who have received previous chemotherapy, biological agents, or radiotherapy.

• Prior transarterial chemoembolisation (TACE) or transarterial embolisation (TAE).

• Prior liver transplantation or liver resection.

• Current or recent (within 10 days of study start) use of full-dose anticoagulants for therapeutic purposes.

• Patients with high risk esophageal/gastric varices.

• The participant has central nervous system (CNS) metastases or carcinomatous meningitis

• The participant has poorly-controlled hypertension [in other words (ie), blood pressure in abnormal range despite medical management]